Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases

Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases
July 10, 2017
News

Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, held an event to launch their latest innovative type 2 diabetes treatment in Lebanon. The event brought together leading experts in internal medicine and primary care physicians to highlight the latest innovative, convenient medical solutions and...

358
0
Like
1 year ago
Do NOT follow this link or you will be banned from the site!